SCOPE: Epidemiologic evidence supports that dietary quercetin reduces cardiovascular disease (CVD) risk, but its oral bioavailability is paradoxically low. The aim of this study was to determine whether dietary fat would improve quercetin bioavailability in adults at high risk for CVD and to assess lipid-mediated micellarization of quercetin in vitro. METHODS AND RESULTS: In a randomized, cross-over study, overweight/obese men and postmenopausal women (n = 4 M/5 F; 55.9 ± 2.1 years; 30.8 ± 1.4 kg/m(2) ) ingested 1095 mg of quercetin aglycone with a standardized breakfast that was fat-free (<0.5 g), low-fat (4.0 g), or high-fat (15.4 g). Plasma was obtained at timed intervals for 24 h to measure quercetin and its methylated metabolites isorhamnetin and tamarixetin. Compared to the fat-free trial, plasma quercetin maximum concentration (Cmax ), and area under curve (AUC0-24 h ) increased (p < 0.05) by 45 and 32%, respectively, during the high-fat trial. During the high-fat trial, isorhamnetin Cmax and AUC0-24 h also increased by 40 and 19%, respectively, whereas Cmax and AUC0-24 h of tamarixetin increased by 46 and 43%, respectively. Dietary fat dose-dependently increased micellarization efficiency of quercetin aglycone in vitro. CONCLUSION:Dietary fat improves quercetin bioavailability by increasing its absorption, likely by enhancing its micellarization at the small intestine.
RCT Entities:
SCOPE: Epidemiologic evidence supports that dietary quercetin reduces cardiovascular disease (CVD) risk, but its oral bioavailability is paradoxically low. The aim of this study was to determine whether dietary fat would improve quercetin bioavailability in adults at high risk for CVD and to assess lipid-mediated micellarization of quercetin in vitro. METHODS AND RESULTS: In a randomized, cross-over study, overweight/obesemen and postmenopausal women (n = 4 M/5 F; 55.9 ± 2.1 years; 30.8 ± 1.4 kg/m(2) ) ingested 1095 mg of quercetin aglycone with a standardized breakfast that was fat-free (<0.5 g), low-fat (4.0 g), or high-fat (15.4 g). Plasma was obtained at timed intervals for 24 h to measure quercetin and its methylated metabolites isorhamnetin and tamarixetin. Compared to the fat-free trial, plasma quercetin maximum concentration (Cmax ), and area under curve (AUC0-24 h ) increased (p < 0.05) by 45 and 32%, respectively, during the high-fat trial. During the high-fat trial, isorhamnetin Cmax and AUC0-24 h also increased by 40 and 19%, respectively, whereas Cmax and AUC0-24 h of tamarixetin increased by 46 and 43%, respectively. Dietary fat dose-dependently increased micellarization efficiency of quercetin aglycone in vitro. CONCLUSION: Dietary fat improves quercetin bioavailability by increasing its absorption, likely by enhancing its micellarization at the small intestine.
Authors: T M Henagan; W T Cefalu; D M Ribnicky; R C Noland; K Dunville; W W Campbell; L K Stewart; L A Forney; T W Gettys; J S Chang; C D Morrison Journal: Genes Nutr Date: 2014-12-27 Impact factor: 5.523
Authors: Torsten Bohn; Gordon J McDougall; Amparo Alegría; Marie Alminger; Eva Arrigoni; Anna-Marja Aura; Catarina Brito; Antonio Cilla; Sedef N El; Sibel Karakaya; Marie C Martínez-Cuesta; Claudia N Santos Journal: Mol Nutr Food Res Date: 2015-06-03 Impact factor: 5.914
Authors: Richard Draijer; Ferdi A van Dorsten; Yvonne E Zebregs; Boudewijn Hollebrands; Sonja Peters; Guus S Duchateau; Christian H Grün Journal: Nutrients Date: 2016-12-15 Impact factor: 5.717
Authors: Jennifer L Jacobi; Bo Yang; Xu Li; Anna K Menze; Sara M Laurentz; Elsa M Janle; Mario G Ferruzzi; George P McCabe; Clint Chapple; Ann L Kirchmaier Journal: PLoS One Date: 2016-02-16 Impact factor: 3.240